AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2024

Jun 24, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2024-06-20

Reporting Person: Scadden David (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-20	Restricted stock units	$	A	2120	Acquired		Common stock (2120)	Direct
2024-06-20	Stock options (right to buy)	$42.45	A	11774	Acquired	2034-06-20	Common stock (11774)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025.